Low-dose Venetoclax and Azacitidine as Front-line Therapy in Newly Diagnosed AML

Patients will receive oral Venetoclax at a fixed dose of 100mg/day from day 1 to day 21 per cycle for a maximum of 2 cycles.

Patients will receive oral itraconazole at a dose of 100 mg every 12 hours from day 1 to day 21.

Patients will receive a maximum of two cycles of daily subcutaneous Azacitidine at a dose of 75 mg/m2 (maximum 100 mg) from day 1 to day 7.